ADVM vs. GLUE, RGNX, RVNC, TSHA, CTNM, ALMS, CRVS, PGEN, TNGX, and TRVI
Should you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Monte Rosa Therapeutics (GLUE), REGENXBIO (RGNX), Revance Therapeutics (RVNC), Taysha Gene Therapies (TSHA), Contineum Therapeutics (CTNM), Alumis (ALMS), Corvus Pharmaceuticals (CRVS), Precigen (PGEN), Tango Therapeutics (TNGX), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry.
Adverum Biotechnologies vs.
Monte Rosa Therapeutics (NASDAQ:GLUE) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.
Adverum Biotechnologies received 355 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 60.20% of users gave Adverum Biotechnologies an outperform vote while only 46.67% of users gave Monte Rosa Therapeutics an outperform vote.
Monte Rosa Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.
Monte Rosa Therapeutics' return on equity of -62.68% beat Adverum Biotechnologies' return on equity.
Adverum Biotechnologies has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.
80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are held by institutional investors. 6.5% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 1 mentions for Monte Rosa Therapeutics and 0 mentions for Adverum Biotechnologies. Monte Rosa Therapeutics' average media sentiment score of 0.47 beat Adverum Biotechnologies' score of 0.00 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.
Monte Rosa Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 147.35%. Adverum Biotechnologies has a consensus price target of $27.83, indicating a potential upside of 542.80%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, analysts plainly believe Adverum Biotechnologies is more favorable than Monte Rosa Therapeutics.
Summary
Monte Rosa Therapeutics and Adverum Biotechnologies tied by winning 8 of the 16 factors compared between the two stocks.
Get Adverum Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adverum Biotechnologies Competitors List
Related Companies and Tools
This page (NASDAQ:ADVM) was last updated on 1/20/2025 by MarketBeat.com Staff
